Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
AC Immune of Switzerland will work with Janssen on a therapeutic Tau-targeted vaccine for Alzheimer’s that is in Phase Ib and which could be used in combination with beta-amyloid based approaches to maximize therapeutic responses to the disease. J&J also has licensed a pioneering microbiome drug from Vedanta.